The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose-response study

Arifulla Khan, G. Virginia Upton, Richard L. Rudolph, Richard Entsuah, Steven M. Leventer, Bernard Baumel, James Claghorn, Lynn Cunningham, Eugene A. DuBoff, James Ferguson, David Goldstein, Jeffrey Allan Mattes, Joseph Mendels, Gary Post, Roger Patrick, Ram Shrivastava, Kenneth Weiss

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

This 12-week, double-blind, placebo-controlled study evaluated the efficacy and safety of venlafaxine as first-line therapy for the treatment of major depression and major depression associated with anxiety in 384 adult outpatients. Fixed total daily dosages of 75, 150, and 200 mg of venlafaxine were administered in a twice-a-day regimen. Primary efficacy parameters were the Hamilton Rating Scale for Depression (HAM-D) total score, the HAM-D Depressed Mood Item, the Montgomery-Asberg Depression Rating Scale total score, and the Clinical Global Impressions Scale. Overall, a higher percentage of patients responded to venlafaxine than to placebo. Efficacy data indicated a dose-related response, most evident in the onset of clinical improvement; statistically significant improvements in some primary parameters were seen as early as 1 to 2 weeks after initiation of treatment, especially in the 150- and 200-mg/day groups. These dose-related clinical improvements continued through week 12. Venlafaxine-treated patients who had depression associated with anxiety showed significant dose-related improvements compared with placebo-treated patients; improvement was noted by scores on the HAM-D Anxiety-Psychic Item and Anxiety-Somatization Factor. Few clinically significant changes were observed in laboratory values, vital signs, or electrocardiogram tracings. Venlafaxine was generally well tolerated at all dosages. The most common study events included nausea, dizziness, somnolence, insomnia, dry mouth, and asthenia, which are consistent with findings of previous studies. The current study demonstrated that 75 to 200 mg/day of venlafaxine twice daily produced a dose-related improvement in the primary efficacy parameters and in the onset of significant antidepressant effects, which was noted at weeks 1 to 2 with the highest dosage tested (200 mg/day). The study also demonstrated that these dosages of venlafaxine were safe and effective as first-line therapy for major depression and depression associated with anxiety.

Original languageEnglish (US)
Pages (from-to)19-25
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume18
Issue number1
DOIs
StatePublished - Feb 1998
Externally publishedYes

Fingerprint

Anxiety
Depression
Placebos
Therapeutics
Asthenia
Vital Signs
Sleep Initiation and Maintenance Disorders
Dizziness
Venlafaxine Hydrochloride
Nausea
Antidepressive Agents
Mouth
Electrocardiography
Outpatients
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety : A dose-response study. / Khan, Arifulla; Upton, G. Virginia; Rudolph, Richard L.; Entsuah, Richard; Leventer, Steven M.; Baumel, Bernard; Claghorn, James; Cunningham, Lynn; DuBoff, Eugene A.; Ferguson, James; Goldstein, David; Mattes, Jeffrey Allan; Mendels, Joseph; Post, Gary; Patrick, Roger; Shrivastava, Ram; Weiss, Kenneth.

In: Journal of Clinical Psychopharmacology, Vol. 18, No. 1, 02.1998, p. 19-25.

Research output: Contribution to journalArticle

Khan, A, Upton, GV, Rudolph, RL, Entsuah, R, Leventer, SM, Baumel, B, Claghorn, J, Cunningham, L, DuBoff, EA, Ferguson, J, Goldstein, D, Mattes, JA, Mendels, J, Post, G, Patrick, R, Shrivastava, R & Weiss, K 1998, 'The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose-response study', Journal of Clinical Psychopharmacology, vol. 18, no. 1, pp. 19-25. https://doi.org/10.1097/00004714-199802000-00004
Khan, Arifulla ; Upton, G. Virginia ; Rudolph, Richard L. ; Entsuah, Richard ; Leventer, Steven M. ; Baumel, Bernard ; Claghorn, James ; Cunningham, Lynn ; DuBoff, Eugene A. ; Ferguson, James ; Goldstein, David ; Mattes, Jeffrey Allan ; Mendels, Joseph ; Post, Gary ; Patrick, Roger ; Shrivastava, Ram ; Weiss, Kenneth. / The use of venlafaxine in the treatment of major depression and major depression associated with anxiety : A dose-response study. In: Journal of Clinical Psychopharmacology. 1998 ; Vol. 18, No. 1. pp. 19-25.
@article{51f6576f2e274ffabe9480a5fd31c5b7,
title = "The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose-response study",
abstract = "This 12-week, double-blind, placebo-controlled study evaluated the efficacy and safety of venlafaxine as first-line therapy for the treatment of major depression and major depression associated with anxiety in 384 adult outpatients. Fixed total daily dosages of 75, 150, and 200 mg of venlafaxine were administered in a twice-a-day regimen. Primary efficacy parameters were the Hamilton Rating Scale for Depression (HAM-D) total score, the HAM-D Depressed Mood Item, the Montgomery-Asberg Depression Rating Scale total score, and the Clinical Global Impressions Scale. Overall, a higher percentage of patients responded to venlafaxine than to placebo. Efficacy data indicated a dose-related response, most evident in the onset of clinical improvement; statistically significant improvements in some primary parameters were seen as early as 1 to 2 weeks after initiation of treatment, especially in the 150- and 200-mg/day groups. These dose-related clinical improvements continued through week 12. Venlafaxine-treated patients who had depression associated with anxiety showed significant dose-related improvements compared with placebo-treated patients; improvement was noted by scores on the HAM-D Anxiety-Psychic Item and Anxiety-Somatization Factor. Few clinically significant changes were observed in laboratory values, vital signs, or electrocardiogram tracings. Venlafaxine was generally well tolerated at all dosages. The most common study events included nausea, dizziness, somnolence, insomnia, dry mouth, and asthenia, which are consistent with findings of previous studies. The current study demonstrated that 75 to 200 mg/day of venlafaxine twice daily produced a dose-related improvement in the primary efficacy parameters and in the onset of significant antidepressant effects, which was noted at weeks 1 to 2 with the highest dosage tested (200 mg/day). The study also demonstrated that these dosages of venlafaxine were safe and effective as first-line therapy for major depression and depression associated with anxiety.",
author = "Arifulla Khan and Upton, {G. Virginia} and Rudolph, {Richard L.} and Richard Entsuah and Leventer, {Steven M.} and Bernard Baumel and James Claghorn and Lynn Cunningham and DuBoff, {Eugene A.} and James Ferguson and David Goldstein and Mattes, {Jeffrey Allan} and Joseph Mendels and Gary Post and Roger Patrick and Ram Shrivastava and Kenneth Weiss",
year = "1998",
month = "2",
doi = "10.1097/00004714-199802000-00004",
language = "English (US)",
volume = "18",
pages = "19--25",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The use of venlafaxine in the treatment of major depression and major depression associated with anxiety

T2 - A dose-response study

AU - Khan, Arifulla

AU - Upton, G. Virginia

AU - Rudolph, Richard L.

AU - Entsuah, Richard

AU - Leventer, Steven M.

AU - Baumel, Bernard

AU - Claghorn, James

AU - Cunningham, Lynn

AU - DuBoff, Eugene A.

AU - Ferguson, James

AU - Goldstein, David

AU - Mattes, Jeffrey Allan

AU - Mendels, Joseph

AU - Post, Gary

AU - Patrick, Roger

AU - Shrivastava, Ram

AU - Weiss, Kenneth

PY - 1998/2

Y1 - 1998/2

N2 - This 12-week, double-blind, placebo-controlled study evaluated the efficacy and safety of venlafaxine as first-line therapy for the treatment of major depression and major depression associated with anxiety in 384 adult outpatients. Fixed total daily dosages of 75, 150, and 200 mg of venlafaxine were administered in a twice-a-day regimen. Primary efficacy parameters were the Hamilton Rating Scale for Depression (HAM-D) total score, the HAM-D Depressed Mood Item, the Montgomery-Asberg Depression Rating Scale total score, and the Clinical Global Impressions Scale. Overall, a higher percentage of patients responded to venlafaxine than to placebo. Efficacy data indicated a dose-related response, most evident in the onset of clinical improvement; statistically significant improvements in some primary parameters were seen as early as 1 to 2 weeks after initiation of treatment, especially in the 150- and 200-mg/day groups. These dose-related clinical improvements continued through week 12. Venlafaxine-treated patients who had depression associated with anxiety showed significant dose-related improvements compared with placebo-treated patients; improvement was noted by scores on the HAM-D Anxiety-Psychic Item and Anxiety-Somatization Factor. Few clinically significant changes were observed in laboratory values, vital signs, or electrocardiogram tracings. Venlafaxine was generally well tolerated at all dosages. The most common study events included nausea, dizziness, somnolence, insomnia, dry mouth, and asthenia, which are consistent with findings of previous studies. The current study demonstrated that 75 to 200 mg/day of venlafaxine twice daily produced a dose-related improvement in the primary efficacy parameters and in the onset of significant antidepressant effects, which was noted at weeks 1 to 2 with the highest dosage tested (200 mg/day). The study also demonstrated that these dosages of venlafaxine were safe and effective as first-line therapy for major depression and depression associated with anxiety.

AB - This 12-week, double-blind, placebo-controlled study evaluated the efficacy and safety of venlafaxine as first-line therapy for the treatment of major depression and major depression associated with anxiety in 384 adult outpatients. Fixed total daily dosages of 75, 150, and 200 mg of venlafaxine were administered in a twice-a-day regimen. Primary efficacy parameters were the Hamilton Rating Scale for Depression (HAM-D) total score, the HAM-D Depressed Mood Item, the Montgomery-Asberg Depression Rating Scale total score, and the Clinical Global Impressions Scale. Overall, a higher percentage of patients responded to venlafaxine than to placebo. Efficacy data indicated a dose-related response, most evident in the onset of clinical improvement; statistically significant improvements in some primary parameters were seen as early as 1 to 2 weeks after initiation of treatment, especially in the 150- and 200-mg/day groups. These dose-related clinical improvements continued through week 12. Venlafaxine-treated patients who had depression associated with anxiety showed significant dose-related improvements compared with placebo-treated patients; improvement was noted by scores on the HAM-D Anxiety-Psychic Item and Anxiety-Somatization Factor. Few clinically significant changes were observed in laboratory values, vital signs, or electrocardiogram tracings. Venlafaxine was generally well tolerated at all dosages. The most common study events included nausea, dizziness, somnolence, insomnia, dry mouth, and asthenia, which are consistent with findings of previous studies. The current study demonstrated that 75 to 200 mg/day of venlafaxine twice daily produced a dose-related improvement in the primary efficacy parameters and in the onset of significant antidepressant effects, which was noted at weeks 1 to 2 with the highest dosage tested (200 mg/day). The study also demonstrated that these dosages of venlafaxine were safe and effective as first-line therapy for major depression and depression associated with anxiety.

UR - http://www.scopus.com/inward/record.url?scp=0031963340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031963340&partnerID=8YFLogxK

U2 - 10.1097/00004714-199802000-00004

DO - 10.1097/00004714-199802000-00004

M3 - Article

C2 - 9472838

AN - SCOPUS:0031963340

VL - 18

SP - 19

EP - 25

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -